Bank of Hawaii lifted its stake in Eli Lilly and Co (NYSE:LLY) by 17.4% in the 4th quarter, HoldingsChannel reports. The fund owned 9,013 shares of the company’s stock after purchasing an additional 1,335 shares during the quarter. Bank of Hawaii’s holdings in Eli Lilly and were worth $761,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. raised its position in shares of Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in shares of Eli Lilly and by 0.8% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after acquiring an additional 24 shares in the last quarter. Pathstone Family Office LLC raised its position in shares of Eli Lilly and by 100.0% in the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after acquiring an additional 29 shares in the last quarter. Princeton Portfolio Strategies Group LLC raised its position in shares of Eli Lilly and by 0.3% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 17,860 shares of the company’s stock worth $1,470,000 after acquiring an additional 53 shares in the last quarter. Finally, Strategic Advisors LLC raised its position in shares of Eli Lilly and by 1.2% in the 2nd quarter. Strategic Advisors LLC now owns 4,765 shares of the company’s stock worth $392,000 after acquiring an additional 58 shares in the last quarter. 75.71% of the stock is owned by hedge funds and other institutional investors.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the sale, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 260,486 shares of company stock worth $22,795,340. Company insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $78.75 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.03 and a current ratio of 1.32. The firm has a market capitalization of $86,710.00, a PE ratio of 48.61, a price-to-earnings-growth ratio of 1.44 and a beta of 0.23. Eli Lilly and Co has a one year low of $73.69 and a one year high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The business had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.95 EPS. equities research analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is presently 138.89%.
Several research analysts have recently commented on the company. BMO Capital Markets boosted their price target on Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a research report on Thursday, February 1st. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Morgan Stanley boosted their target price on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 21st. Finally, Bank of America dropped their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $93.22.
TRADEMARK VIOLATION WARNING: “Bank of Hawaii Buys 1,335 Shares of Eli Lilly and Co (LLY)” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://transcriptdaily.com/2018/02/25/bank-of-hawaii-buys-1335-shares-of-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.